Nachrichten zur Eli Lilly & Co. Aktie

More Good News for Eli Lilly Sends the Stock Even Higher

Lillys experimental GLP-1 is effective in treating osteoarthritic knee pain.…

More Good News for Eli Lilly Sends the Stock Even Higher

Lillys experimental GLP-1 is effective in treating osteoarthritic knee pain.…

Eli Lilly secures first approval for weight-loss pill in China

Eli Lilly and Co (NYSE:LLY), the American pharmaceutical group, has become the first drugmaker to secure Chinese approval for an…

Eli Lilly – Warum die Kursrally noch nicht zu Ende sein dürfte!

Für mich ist Eli Lilly (LLY) nach der jüngsten Rally weiterhin einer der spannendsten Leader-Stocks im Gesundheitssektor. Die Zulassung der…

Vorsprung im Milliardenmarkt: China lässt erste Abnehmpille von Eli Lilly zu

First-Mover-Vorteil in China: Die chinesische Arzneimittelbehörde erteilt dem oralen Adipositas-Präparat Orforglipron als erstem Medikament seiner Klasse die Marktzulassung. Strategischer...…

Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval

Lilly plans to file by the end of the year for U.S. approval of the daily pill for moderate-to-severe obstructive…

Unerschlossene Märkte: Jefferies sieht weltweites GLP-1-Potenzial von Eli Lilly noch unterschätzt

Optimistischeres Kursziel: Jefferies hebt die Zielmarke für Eli Lilly auf 1.700 US-Dollar an und bekräftigt die Kaufempfehlung. Wachstumshebel Ausland:…

Hims & Hers Health short interest rises to 23% ahead of Q3 results

Short interest in Hims & Hers Health rose to 23%, making it one of the most shorted mid-cap stocks. Stock…

Eli Lilly Partners With Hims & Hers to Expand GLP-1 Access

Eli Lilly partners with Hims & Hers to expand access to obesity drugs, with CEO Andrew Dudum highlighting the benefits…

Is Hims & Hers Health (HIMS) A Bargain After Its Lilly Deal?

Eli Lilly’s new agreement with Hims & Hers Health (HIMS) puts Lilly’s obesity drugs Zepbound and Foundayo directly inside the…

Hims & Hers Health (HIMS) Could Be 85% Undervalued Following The Eli Lilly Deal

Hims & Hers Health (HIMS) just signed a new agreement with Eli Lilly that allows its users to access branded…

Hims Partnership Could Be A Big Deal For Eli Lilly (LLY)

Eli Lilly and Hims & Hers Health announced a partnership in early November 2026 that lets eligible patients obtain Zepbound…

Hims & Hers Stock After Lilly Weight Loss Drug Deal Has The Bull Case Changed?

Eli Lilly and Company announced an agreement with Hims & Hers Health to offer FDA-approved obesity drugs Zepbound and Foundayo…

Hims & Hers Health (HIMS) Adds FDA Approved Obesity Drugs To Its Platform

Hims & Hers Health (NYSE:HIMS) announced a new partnership with Eli Lilly to offer Zepbound and Foundayo on its platform.…

Eli Lilly Is Much More Than a Weight-Loss Drug Company. Heres the Evidence

Eli Lilly could thrive even as competition in the weight-loss market intensifies.…

Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs

Hims & Hers struck a deal with Eli Lilly to offer the drugmaker’s branded obesity treatments through its online health…

Healthcare Stocks Were Flat, But Biotech Found A Pulse

Moderna raised its full-year outlook as Natera slid on a wider-than-expected Q3 loss and Hims & Hers gained on a…

Eli Lilly Integrates Zepbound and Foundayo Into Hims & Hers, Completing Cash-Pay GLP-1 Platform

Eli Lilly’s formal partnership with Hims & Hers puts Zepbound ($299/mo) and Foundayo ($149/mo) inside the telehealth platform as of…

Eli Lilly Strikes Surprising Deal With Hims & Hers

Wall Street sees opportunity, but profitability questions remain unresolved.…

Eli Lilly (LLY) Widens Access To Its Obesity Drugs Through Telehealth

Eli Lilly (NYSE:LLY) is partnering with Hims & Hers Health and LifeMD to offer FDA-approved obesity drugs through telehealth platforms.The…

Lilly, Hims Partner to Expand Access to Obesity Drugs

Eli Lilly joins Hims to offer discounted GLP-1 weight-loss drugs via telehealth, widening access, boosting Hims and preserving Lillys branded…

Eli Lilly Teams Up With Hims Platform for Direct Delivery of Weight-Loss Drugs as Cash-Pay Channel Battle Heats Up

Eli Lilly and telehealth platform Hims & Hers announced a partnership on Friday under which Hims users who complete an…

Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs

Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs…

Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery - Eli Lilly (NYSE:LLY), Hims & Hers…

Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting…

Hims & Hers rises 5% as Eli Lilly deal brings $149 obesity pill access

Telehealth provider Hims & Hers Health (NYSE:HIMS) shares rose 5% to $25.32 during the Nov. 6 trading session. In a…

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro

Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its…

Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines

The agreement provides access for prescribed patients to Lillys obesity medicines self-pay pricing starting at $149 per month without leaving…

Lilly to sell Zepbound and Foundayo on Hims & Hers platform

Eli Lilly will sell obesity drugs Zepbound and Foundayo directly through Hims & Hers in the United States under an…

Hims Surges On Surprising And Inevitable Deal With Eli Lilly

Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the companys obesity drugs.…

Eli Lilly is partnering with Hims & Hers to sell its weight loss drugs

The agreement covers Zepbound and Foundayo for patients who pay out of pocket through the telehealth platform…

Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement

Hims & Hers stock rises after the company announces an agreement with Eli Lilly to offer the pharma giant’s GLP-1s…

Lilly to sell obesity drugs directly on Hims & Hers site

Nov 6 (Reuters) - Eli Lilly said on Friday it struck a deal to allow Hims & Hers Health to…

Eli Lilly teams up with Hims & Hers on obesity drugs

Hims & Hers already has a similar partnership with Denmark’s Novo Nordisk.…

Hims & Hers gains on partnership with Eli Lilly

Hims & Hers Health (HIMS) stock rises as the company inks a partnership to sell Eli Lillys (LLY) weight-loss drugs,…

Lilly and Hims & Hers Formalize Self-Pay Obesity Drug Access

Eli Lilly and Hims & Hers announced an agreement on November 6, 2026 to expand access to Zepbound and Foundayo…

Lilly partners with Hims & Hers on obesity drug sales

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies sold directly on the…

Lilly to sell obesity drugs directly on Hims & Hers site

Nov 6 (Reuters) - Eli Lilly said on Friday it struck a deal to allow telehealth company Hims & Hers…

Hims & Hers rises 5% as Eli Lilly deal brings $149 obesity pill access

Telehealth provider Hims & Hers Health (NYSE:HIMS) shares rose 5% to $25.32 during the Nov. 6 trading session. In a separate…

2 Defensive Healthcare Stocks Hitting New 52-Week Highs: ABBV & LLY

As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure…

Eli Lilly gets BofA target hike as non-obesity pipeline takes focus

Eli Lilly and Co (NYSE:LLY) received a higher price target of $1,557 from Bank of America, which maintained its "buy" rating…

Santoli: AI bull market almost surely needs tech stocks to recover to keep advancing

The road to bull-market glory does not run through Walmart and Berkshire Hathaway and Eli Lilly.…

Eli Lilly Posts Strong Quarterly Results and Hits Record High Stock Price

Eli Lilly (LLY) delivered strong third-quarter revenue and core drug sales, and the company raised its revenue guidance, confirming business…

Unprecedented weight-loss drug craze pushing Lilly to near-record highs

Morgan Stanley raised Eli Lillys price target as demand for Zepbound and Mounjaro skyrockets.…

Eli Lilly Stock: Is It Still a Buy at $1,400?

The company just released some incredible quarterly results, but its valuation is also fairly high.…

Eli Lilly stock surges as cheaper drugs unlock a bigger market

Lilly shares hit a record as weight-loss drugs became more accessible.…

After Eli Lilly’s Explosive Earnings Report, Is It Too Late to Buy the Stock?

Eli Lilly stock is trading at a record high.…

Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030

GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.…

Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030

GLP-1 weight loss drugs are propelling profits for some drugmakers like Eli Lilly.…

Eli Lilly Is Now Worth as Much as Warren Buffetts Berkshire Hathaway. Can the Rally Keep Going?

Eli Lillys business is heavily driven by one product, while Berkshire Hathaway is a diversified conglomerate.…

Eli Lilly raises earnings outlook as obesity drug demand drives strong growth, UBS says

Eli Lilly and Co (NYSE:LLY) is benefiting from exceptional global demand for its obesity and diabetes medicines, with strong sales…